The role of p38 mitogen-activated kinase (MAPK) in the mechanism regulating cyclooxygenase gene expression in equine leukocytes

Veterinary Immunology and Immunopathology

Volumn 118, Issue 3-4, 2007, Pages 294-303

  Eckert, Rachael E ^a   Neuder, Laura E ^a   Bell, Jennifer L ^a   Trujillo, Jennifer C ^a   Jones, Samuel L ^a  

^a NORTH CAROLINA STATE UNIVERSITY   (United States)

Author keywords

Endotoxin shock; Inflammation; Lipopolysaccharide; Other animals

Indexed keywords

4 (4 FLUOROPHENYL) 2 (4 HYDROXYPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; 4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; INTERLEUKIN 1; LIPOPOLYSACCHARIDE; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE P38; MITOGEN ACTIVATED PROTEIN KINASE P38 INHIBITOR; PROSTAGLANDIN E2; PROSTAGLANDIN SYNTHASE; PROSTANOID; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DRUG TARGETING; ENDOTOXEMIA; GENE EXPRESSION REGULATION; HORSE; HYPOTHESIS; IMMUNOPATHOLOGY; IMMUNOSTIMULATION; INFLAMMATION; INHIBITION KINETICS; LEUKOCYTE; MOLECULAR DYNAMICS; NONHUMAN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; UPREGULATION;

ANIMALS; CELLS, CULTURED; CYCLOOXYGENASE 2; ENZYME ACTIVATION; EPOPROSTENOL; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HORSES; IMIDAZOLES; LEUKOCYTES; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PROSTAGLANDINS; PYRIDINES; RNA, MESSENGER; TIME FACTORS;

ANIMALIA; EQUIDAE;

EID: 34447256369     PISSN: 01652427     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vetimm.2007.06.001     Document Type: Article

References (50)

1. Arbabi S., Rosengart M.R., Garcia I., and Maier R.V. Hypertonic saline solution induces prostacyclin production by increasing cyclooxygenase-2 expression. Surgery 128 (2000) 198-205
2. Badger A.M., Bradbeer J.N., Votta B., Lee J.C., Adams J.L., and Griswold D.E. Pharmacological profile of SB 203580, a selective inhibitor of cytokine suppressive binding protein/p38 kinase, in animal models of arthritis, bone resorption, endotoxin shock and immune function. J. Pharmacol. Exp. Ther. 279 (1996) 1453-1461
3. Beardmore V.A., Hinton H.J., Eftychi C., Apostolaki M., Armaka M., Darragh J., McIlrath J., Carr J.M., Armit L.J., Clacher C., Malone L., Kollias G., and Arthur J.S. Generation and characterization of p38 beta (MAPK11) gene-targeted mice. Mol. Cell Biol. 25 (2005) 10454-10464
4. Bottoms G.D., Templeton C.B., Fessler J.F., Johnson M.A., Roesel O.F., Ewert K.M., and Adams S.B. Thromboxane, prostaglandin I2 (epoprostenol), and the hemodynamic changes in equine endotoxin shock. Am. J. Vet. Res. 43 (1982) 999-1002
5. Bottoms G.D., and Adams H.R. Involvement of prostaglandins and leukotrienes in the pathogenesis of endotoxemia and sepsis. J. Am. Vet. Med. Assoc. 200 (1992) 1842-1848
6. Brady C.A., and Otto C.M. Systemic inflammatory response syndrome, sepsis, and multiple organ dysfunction. Vet. Clin. N. Am. Small Anim Pract. 31 (2001) 1147-1162
7. Branger J., van den B.B., Weijer S., Madwed J., Bos C.L., Gupta A., Yong C.L., Polmar S.H., Olszyna D.P., Hack C.E., van Deventer S.J., Peppelenbosch M.P., and van der P.T. Anti-inflammatory effects of a p38 mitogen-activated protein kinase inhibitor during human endotoxemia. J. Immunol. 168 (2002) 4070-4077
8. Branger J., van den B.B., Weijer S., Gupta A., van Deventer S.J., Hack C.E., Peppelenbosch M.P., and van der P.T. Inhibition of coagulation, fibrinolysis, and endothelial cell activation by a p38 mitogen-activated protein kinase inhibitor during human endotoxemia. Blood 101 (2003) 4446-4448
9. Bulger E.M., and Maier R.V. Lipid mediators in the pathophysiology of critical illness. Crit. Care Med. 28 (2000) N27-N36
10. Caput D., Beutler B., Hartog K., Thayer R., Brown-Shimer S., and Cerami A. Identification of a common nucleotide sequence in the 3′-untranslated region of mRNA molecules specifying inflammatory mediators. Proc. Natl. Acad. Sci. U.S.A. 83 (1986) 1670-1674
11. Chen C., Chen Y.H., and Lin W.W. Involvement of p38 mitogen-activated protein kinase in lipopolysaccharide-induced iNOS and COX-2 expression in J774 macrophages. Immunology 97 (1999) 124-129
12. Cuenda A., Rouse J., Doza Y.N., Meier R., Cohen P., Gallagher T.F., Young P.R., and Lee J.C. SB 203580 is a specific inhibitor of a MAP kinase homologue which is stimulated by cellular stresses and interleukin-1. FEBS Lett. 364 (1995) 229-233
13. Davies S.P., Reddy H., Caivano M., and Cohen P. Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem. J. 351 (2000) 95-105
14. Dean J.L., Brook M., Clark A.R., and Saklatvala J. p38 mitogen-activated protein kinase regulates cyclooxygenase-2 mRNA stability and transcription in lipopolysaccharide-treated human monocytes. J. Biol. Chem. 274 (1999) 264-269
15. Dean J.L., Sarsfield S.J., Tsounakou E., and Saklatvala J. p38 mitogen-activated protein kinase stabilizes mRNAs that contain cyclooxygenase-2 and tumor necrosis factor AU-rich elements by inhibiting deadenylation. J. Biol. Chem. 278 (2003) 39470-39476
16. English J.M., and Cobb M.H. Pharmacological inhibitors of MAPK pathways. Trends Pharmacol. Sci. 23 (2002) 40-45
17. Fijen J.W., Zijlstra J.G., De Boer P., Spanjersberg R., Tervaert J.W., Van Der Werf T.S., Ligtenberg J.J., and Tulleken J.E. Suppression of the clinical and cytokine response to endotoxin by RWJ-67657, a p38 mitogen-activated protein-kinase inhibitor, in healthy human volunteers. Clin. Exp. Immunol. 124 (2001) 16-20
18. Frantz B., Klatt T., Pang M., Parsons J., Rolando A., Williams H., Tocci M.J., O'Keefe S.J., and O'Neill E.A. The activation state of p38 mitogen-activated protein kinase determines the efficiency of ATP competition for pyridinylimidazole inhibitor binding. Biochemistry 37 (1998) 13846-13853
19. Grosser T., Fries S., and FitzGerald G.A. Biological basis for the cardiovascular consequences of COX-2 inhibition: therapeutic challenges and opportunities. J. Clin. Invest. 116 (2006) 4-15
20. Hale K.K., Trollinger D., Rihanek M., and Manthey C.L. Differential expression and activation of p38 mitogen-activated protein kinase alpha, beta, gamma, and delta in inflammatory cell lineages. J. Immunol. 162 (1999) 4246-4252
21. Han J., Jiang Y., Li Z., Kravchenko V.V., and Ulevitch R.J. Activation of the transcription factor MEF2C by the MAP kinase p38 in inflammation. Nature 386 (1997) 296-299
22. Jiang Y., Gram H., Zhao M., New L., Gu J., Feng L., di Padova F., Ulevitch R.J., and Han J. Characterization of the structure and function of the fourth member of p38 group mitogen-activated protein kinases, p38 delta. J. Biol. Chem. 272 (1997) 30122-30128
23. Kumar S., Boehm J., and Lee J.C. p38 MAP kinases: key signalling molecules as therapeutic targets for inflammatory diseases. Nat. Rev. Drug Discov. 2 (2003) 717-726
24. Kumar S., Orsini M.J., Lee J.C., McDonnell P.C., Debouck C., and Young P.R. Activation of the HIV-1 long terminal repeat by cytokines and environmental stress requires an active CSBP/p38 MAP kinase. J. Biol. Chem. 271 (1996) 30864-30869
25. Kyriakis J.M., and Avruch J. Mammalian mitogen-activated protein kinase signal transduction pathways activated by stress and inflammation. Physiol. Rev. 81 (2001) 807-869
26. Lai W.C., Zhou M., Shankavaram U., Peng G., and Wahl L.M. Differential regulation of lipopolysaccharide-induced monocyte matrix metalloproteinase (MMP)-1 and MMP-9 by p38 and extracellular signal-regulated kinase 1/2 mitogen-activated protein kinases. J. Immunol. 170 (2003) 6244-6249
27. Lascelles B.D., Blikslager A.T., Fox S.M., and Reece D. Gastrointestinal tract perforation in dogs treated with a selective cyclooxygenase-2 inhibitor: 29 cases (2002-2003). J. Am. Vet. Med. Assoc. 227 (2005) 1112-1117
28. Moore J.N., Garner H.E., Shapland J.E., and Schaub R.G. Equine endotoxemia: an insight into cause and treatment. J. Am. Vet. Med. Assoc. 179 (1981) 473-477
29. Moore J.N., and Barton M.H. An update on endotoxemia. Part I. Mechanisms and pathways. Equine Vet. Educ. 10 (1998) 300-306
30. Mukherjee D., Nissen S.E., and Topol E.J. Risk of cardiovascular events associated with selective COX-2 inhibitors. JAMA 286 (2001) 954-959
31. Nagano S., Otsuka T., Niiro H., Yamaoka K., Arinobu Y., Ogami E., Akahoshi M., Inoue Y., Miyake K., Nakashima H., Niho Y., and Harada M. Molecular mechanisms of lipopolysaccharide-induced cyclooxygenase-2 expression in human neutrophils: involvement of the mitogen-activated protein kinase pathway and regulation by anti-inflammatory cytokines. Int. Immunol. 14 (2002) 733-740
32. Nick J.A., Avdi N.J., Young S.K., Lehman L.A., McDonald P.P., Frasch S.C., Billstrom M.A., Henson P.M., Johnson G.L., and Worthen G.S. Selective activation and functional significance of p38 alpha mitogen-activated protein kinase in lipopolysaccharide-stimulated neutrophils. J. Clin. Invest. 103 (1999) 851-858
33. Parrillo J.E. Pathogenetic mechanisms of septic shock. N. Engl. J. Med. 328 (1993) 1471-1477
34. Peng T., Lu X., Lei M., Moe G.W., and Feng Q. Inhibition of p38 MAPK decreases myocardial TNF-alpha expression and improves myocardial function and survival in endotoxemia. Cardiovasc. Res. 59 (2003) 893-900
35. Prakash J., Sandovici M., Saluja V., Lacombe M., Schaapveld R.Q., de Borst M.H., van Goor H., Henning R.H., Proost J.H., Moolenaar F., Keri G., Meijer D.K., Poelstra K., and Kok R.J. Intracellular delivery of the p38 mitogen-activated protein kinase inhibitor SB202190 [4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)1H-imidazole] in renal tubular cells: a novel strategy to treat renal fibrosis. J. Pharmacol. Exp. Ther. 319 (2006) 8-19
36. Renzi P.M., and Flynn J.T. Endotoxin enhances arachidonic acid metabolism by cultured rabbit microvascular endothelial cells. Am. J. Physiol. 263 (1992) H1213-H1221
37. Rosen G.D., Birkenmeier T.M., Raz A., and Holtzman M.J. Identification of a cyclooxygenase-related gene and its potential role in prostaglandin formation. Biochem. Biophys. Res. Commun. 164 (1989) 1358-1365
38. Shifflett D.E., Jones S.L., Moeser A.J., and Blikslager A.T. Mitogen-activated protein kinases regulate COX-2 and mucosal recovery in ischemic-injured porcine ileum. Am. J. Physiol. Gastrointest. Liver Physiol. 286 (2004) G906-G913
39. Tanabe T., and Tohnai N. Cyclooxygenase isozymes and their gene structures and expression. Prostaglandins Other Lipid Mediat. 68-69 (2002) 95-114
40. Templeton C.B., Bottoms G.D., Fessler J.F., Ewert K.M., Roesel O.F., Johnson M.A., and Latshaw H.S. Endotoxin-induced hemodynamic and prostaglandin changes in ponies: effects of flunixin meglumine, dexamethasone, and prednisolone. Circ. Shock 23 (1987) 231-240
41. Traub-Dargatz J.L., Kopral C.A., Seitzinger A.H., Garber L.P., Forde K., and White N.A. Estimate of the national incidence of and operation-level risk factors for colic among horses in the United States, spring 1998 to spring 1999. J. Am. Vet. Med. Assoc. 219 (2001) 67-71
42. Velentgas P., West W., Cannuscio C.C., Watson D.J., and Walker A.M. Cardiovascular risk of selective cyclooxygenase-2 inhibitors and other non-aspirin non-steroidal anti-inflammatory medications. Pharmacoepidemiol. Drug Saf. 15 (2006) 641-652
43. Waguespack R.W., Cochran A., and Belknap J.K. Expression of the cyclooxygenase isoforms in the prodromal stage of black walnut-induced laminitis in horses. Am. J. Vet. Res. 65 (2004) 1724-1729
44. Wallace J.L. Selective cyclooxygenase-2 inhibitors: after the smoke has cleared. Dig. Liver Dis. 34 (2002) 89-94
45. Wallace J.L., and Devchand P.R. Emerging roles for cyclooxygenase-2 in gastrointestinal mucosal defense. Br. J. Pharmacol. 145 (2005) 275-282
46. Wang X.S., Diener K., Manthey C.L., Wang S., Rosenzweig B., Bray J., Delaney J., Cole C.N., Chan-Hui P.Y., Mantlo N., Lichenstein H.S., Zukowski M., and Yao Z. Molecular cloning and characterization of a novel p38 mitogen-activated protein kinase. J. Biol. Chem. 272 (1997) 23668-23674
47. Warny M., Keates A.C., Keates S., Castagliuolo I., Zacks J.K., Aboudola S., Qamar A., Pothoulakis C., LaMont J.T., and Kelly C.P. p38 MAP kinase activation by Clostridium difficile toxin A mediates monocyte necrosis, IL-8 production, and enteritis. J. Clin. Invest. 105 (2000) 1147-1156
48. Ylikorkala O., and Makila U.M. Prostacyclin and thromboxane in gynecology and obstetrics. Am. J. Obstet. Gynecol. 152 (1985) 318-329
49. Young P.R. Pharmacological modulation of cytokine action and production through signaling pathways. Cytokine Growth Factor Rev. 9 (1998) 239-257
50. Zhao M., New L., Kravchenko V.V., Kato Y., Gram H., di Padova F., Olson E.N., Ulevitch R.J., and Han J. Regulation of the MEF2 family of transcription factors by p38. Mol. Cell Biol. 19 (1999) 21-30